Aprea Therapeutics, Inc. (NASDAQ:APRE) CEO Buys $14,580.00 in Stock

Aprea Therapeutics, Inc. (NASDAQ:APREGet Free Report) CEO Oren Gilad purchased 2,000 shares of Aprea Therapeutics stock in a transaction dated Wednesday, March 13th. The stock was bought at an average price of $7.29 per share, with a total value of $14,580.00. Following the completion of the transaction, the chief executive officer now owns 324,770 shares of the company’s stock, valued at approximately $2,367,573.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE opened at $6.19 on Friday. The stock has a market cap of $23.15 million, a PE ratio of -1.55 and a beta of 1.05. Aprea Therapeutics, Inc. has a fifty-two week low of $2.78 and a fifty-two week high of $8.85. The stock has a fifty day moving average of $6.26 and a 200-day moving average of $4.86.

Hedge Funds Weigh In On Aprea Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Aprea Therapeutics by 26.9% in the fourth quarter. Vanguard Group Inc. now owns 34,688 shares of the company’s stock valued at $163,000 after purchasing an additional 7,347 shares in the last quarter. Royal Bank of Canada grew its position in Aprea Therapeutics by 13,788.0% during the fourth quarter. Royal Bank of Canada now owns 44,025 shares of the company’s stock worth $207,000 after buying an additional 43,708 shares in the last quarter. Geode Capital Management LLC purchased a new position in Aprea Therapeutics during the second quarter worth about $74,000. Millennium Management LLC grew its position in Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after buying an additional 43,293 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC purchased a new position in Aprea Therapeutics during the third quarter worth about $40,000. 23.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.

Recommended Stories

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.